

1 **Chronic Wasting Disease and Atypical forms of BSE and scrapie are**
2 **not transmissible to mice expressing wild-type levels of human PrP**

3
4 **Running title:** CWD and Atypical TSE Transmission to HuTg mice

5
6 Rona Wilson¹, Chris Plinston¹, Nora Hunter¹, Cristina Casalone², Cristiano Corona²,
7 Fabrizio Tagliavini³, Silvia Suardi³, Margherita Ruggerone³, Fabio Moda³, Silvia
8 Graziano⁴, Marco Sbriccoli⁴, Franco Cardone⁴, Maurizio Pocchiarri⁴, Loredana
9 Ingrosso⁴, Thierry Baron⁵, Juergen Richt⁶‡, Olivier Andreoletti⁷, Marion Simmons⁸,
10 Richard Lockey⁸, Jean C. Manson¹, and Rona M Barron^{1*}

11
12 ¹Neuropathogenesis Division, The Roslin Institute and R(D)SVS, University of Edinburgh,
13 Roslin, Midlothian, UK

14
15 ²Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Turin, Italy

16
17 ³IRCCS Foundation, "Carlo Besta" Neurological Institute, Milan, Italy

18
19 ⁴Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Viale Regina
20 Elena 299, 00161 Rome, Italy

21
22 ⁵Agence Nationale de Sécurité Sanitaire, Lyon, France

23
24 ⁶USDA, ARS, National Animal Disease Center, PO Box 70, Ames, IA 50010, USA

25
26 ⁷UMR 1225 Interactions Hôtes-Agents Pathogènes, INRA, Ecole Nationale Vétérinaire, 23
27 chemin des Capelles, B.P. 87614, 31076 Toulouse Cedex 3, France

28
29 ⁸Neuropathology Section, Department of Pathology and Host Susceptibility, Animal Health
30 and Veterinary Laboratories Agency, Addlestone, Surrey, KT15 3NB, UK

31
32
33 ‡ Current affiliation: Department of Diagnostic Medicine/Pathobiology, College of Veterinary
34 Medicine, Kansas State University, Manhattan, United States of America

35
36
37 * Corresponding Author

38
39 Neuropathogenesis Division
40 The Roslin Institute and R(D)SVS, University of Edinburgh
41 Roslin
42 Midlothian, EH25 9PS
43 UK
44 Tel 0131 527 4200
45 Fax 0131 440 0434
46 rona.barron@roslin.ed.ac.uk
47

48 Contents Category: TSE Agents

49 Word count summary: 139

50 Word count main text: 2315

51 Number of tables and figures: 2

52 **Chronic Wasting Disease and Atypical forms of BSE and scrapie are**
53 **not transmissible to mice expressing wild-type levels of human PrP**

54
55 **Summary**

56
57 The association between bovine spongiform encephalopathy (BSE) and variant
58 Creutzfeldt-Jakob disease (vCJD) has demonstrated that cattle TSEs can pose a risk to
59 human health and raises the possibility that other ruminant TSEs may be transmissible
60 to humans. In recent years, several new TSEs in sheep, cattle and deer have been
61 described and the risk posed to humans by these agents is currently unknown. In this
62 study, we inoculated two forms of atypical BSE (BASE and H-type BSE), a chronic
63 wasting disease (CWD) isolate, and seven isolates of atypical scrapie into gene-
64 targeted transgenic (Tg) mice expressing the human prion protein (PrP). Upon
65 challenge with these ruminant TSEs, gene-targeted Tg mice expressing human PrP
66 did not show any signs of disease pathology. These data strongly suggest the presence
67 of a substantial transmission barrier between these recently identified ruminant TSEs
68 and humans.

69
70 **Main Text**

71
72 Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of
73 fatal infectious neurodegenerative diseases that include scrapie in sheep, bovine
74 spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in
75 cervids, and Creutzfeldt-Jakob disease (CJD) in humans. TSEs are characterised by
76 the accumulation in the brain of PrP^{TSE}, which is a protease resistant conformational
77 variant of the normal host encoded cellular prion protein (PrP^c). Due to the infectious
78 nature of TSEs, these diseases can be transmitted via a number of different routes.
79 While TSEs tend to transmit more readily within species they are also able to transmit
80 between species, although efficiency is dependent on both the TSE agent and host.
81 Often transmission to a new species may initially present low transmission rates,
82 however further passage within the new species may result in increased transmission
83 rates and shorter incubation periods. The transmission of BSE to humans through
84 contaminated food is thought to be the cause of the variant form of Creutzfeldt-Jakob
85 disease (vCJD) (Bruce *et al.*, 1997; Hill *et al.*, 1997). This relationship reveals a
86 potential risk of transmission of other ruminant TSEs to humans. In the present study
87 we aimed to assess this risk by using gene-targeted Tg mice expressing human PrP as
88 a model system for investigating transmissibility of several atypical ruminant TSE
89 agents (atypical BSE, atypical scrapie and CWD).

90
91 Until recently, TSE disease in cattle was believed to be caused by a single TSE strain,
92 classical BSE (BSE-C). However, two atypical BSE agents have recently been
93 reported (Biacabe *et al.*, 2004; Casalone *et al.*, 2004; Jacobs *et al.*, 2007; Stack *et al.*,
94 2009), and are identified as H-type BSE (BSE-H) and bovine amyloidotic spongiform
95 encephalopathy (BASE, also named BSE-L). Given the association of classical BSE
96 with vCJD, in the present study we investigated the potential risk of transmission of
97 these atypical forms of BSE to humans. CWD is a fatal, endemic TSE disease
98 affecting free-ranging and captive cervids, including mule deer, white-tailed deer,
99 Rocky Mountain elk and moose. Although CWD has not been reported in Europe,
100 cases have been found in 14 USA states, two Canadian provinces and in South Korea.
101 CWD has been shown to spread via a variety of routes (Denkers *et al.*, 2010;

102 Mathiason *et al.*, 2009; Miller & Williams, 2003; Miller *et al.*, 1998; Sigurdson *et al.*,
103 1999; Trifilo *et al.*, 2007), and transmission between cervids is highly efficient. In
104 addition to brain, spinal cord and lymphoid tissues (Race *et al.*, 2007; Sigurdson *et al.*,
105 1999; Spraker *et al.*, 2002), PrP^{TSE} has also been found in muscle, saliva, urine,
106 fat, blood and antler velvet of CWD-infected cervids (Angers *et al.*, 2006; Angers *et al.*,
107 2009; Haley *et al.*, 2009; Haley *et al.*, 2011; Mathiason *et al.*, 2006; Race *et al.*,
108 2009a). Due to hunting of deer and elk, the possible consumption of CWD-infected
109 meat raises concern over the risk to humans. Furthermore, previous studies have
110 shown the intracerebral and oral transmission of CWD into squirrel monkeys (Race *et al.*,
111 2009b). Atypical scrapie, also known as Nor98, was first identified in 1998 in
112 sheep in Norway (Benestad *et al.*, 2003) and can be distinguished from classical
113 scrapie and BSE by the biochemical features of PrP^{TSE}, and its pathology and
114 transmission characteristics. Despite the fact that no evidence of transmissibility of
115 classical scrapie to humans has ever been obtained, atypical scrapie is a newly
116 identified TSE, and is now known to have been present throughout the BSE epidemic
117 (Benestad *et al.*, 2008; Benestad *et al.*, 2003) thus the risk to humans warrants
118 investigation.

119
120 To address the transmissibility of these recently recognized ruminant TSEs to
121 humans, we performed inoculations of two forms of atypical BSE (BASE and H-
122 type), one isolate of CWD (from white-tailed deer), six field isolates of atypical
123 scrapie, and one sheep passaged isolate of atypical scrapie into a panel of gene-
124 targeted Tg mice expressing human PrP under the same spatial and temporal controls
125 as wild-type PrP (Bishop *et al.*, 2006). Previously, three lines of Tg mice (HuMM,
126 HuMV and HuVV) were generated (Bishop *et al.*, 2006) which represent the genetic
127 diversity in the human population, due to the PrP codon 129-methionine/valine
128 polymorphism. Interestingly, this polymorphism correlates with human susceptibility
129 to TSE, and all confirmed clinical cases of vCJD to date have occurred in individuals
130 who are methionine homozygous at PrP codon 129. In addition we also inoculated
131 these ruminant TSEs into gene-targeted Tg mice expressing bovine PrP (named Bov6
132 mice) and wildtype 129/Ola mice (which have the same genetic background as the
133 human and bovine PrP Tg mice) as controls.

134
135 For experimental setup at The Roslin Institute, groups (n=24) of gene-targeted Tg
136 mice expressing human (HuMM, HuMV and HuVV) or bovine PrP (Bov6) and
137 129/Ola controls were inoculated intracerebrally (i.c.) with 0.02 ml of 10⁻¹ brain
138 homogenate (BASE, BSE-H, CWD or atypical scrapie) into the right cerebral
139 hemisphere under halothane anaesthesia. As inocula were sourced from field cases
140 they were treated with gentamycin (0.25mg/ml) prior to inoculation to remove
141 bacterial contamination. In complementary studies, groups of the same HuMM,
142 HuMV and HuVV mice were also inoculated i.c. (20µl) and i.p.(100 µl) with BASE
143 inoculum at “Carlo Besta” Neurological Institute, Milan, and i.c (20µl) with two
144 different cases of BASE and BSE at the Istituto Superiore di Sanità, Rome, Italy.
145 Mice were scored each week for clinical signs of disease and killed by cervical
146 dislocation or carbon dioxide (Rome, Italy) at a pre-defined clinical endpoint, or due
147 to welfare reasons (Dickinson *et al.*, 1968). Brains and spleens were recovered at post
148 mortem. To assess the abundance and location of TSE-associated vacuolation in grey
149 and white matter of the brain, sections were cut (6µm) from each mouse brain and
150 stained using haematoxylin and eosin (H&E). TSE-related vacuolation was assessed
151 at nine grey-matter regions (medulla, cerebellum, superior colliculus, hypothalamus,

152 thalamus, hippocampus, septum, retrosplinal cortex, cingulated and motor cortex) and
153 three regions of white matter (cerebellar white matter, midbrain white matter, and
154 cerebral peduncle) as previously described (Fraser & Dickinson, 1967). Sections of
155 brain tissue were also examined for abnormal PrP deposition, which is a key
156 pathological marker of TSE infection, by immunohistochemistry and western blot
157 analysis following PTA precipitation using MAb6H4 (Prionics) as described
158 previously (Bishop *et al.*, 2006). Although some mice in these experiments exhibited
159 clinical signs of disease, following analysis of all mice in this study for vacuolar
160 pathology and PrP deposition, no signs of TSE pathology were detected in any of the
161 gene-targeted human PrP Tg mice (Table 1). Transmission of BASE and BSE-H in
162 Bov6 and 129/Ola mice was detected as previously described (Wilson *et al.*, 2012),
163 however no transmission of atypical scrapie was observed in these two control mouse
164 lines.

165
166 Recent studies of TSE inoculations in mice that result in inefficient disease
167 transmission have identified that lymphoid tissues were more permissive to TSEs than
168 brain (Béringue *et al.*, 2012). Tg338 (ovine PrP) mice inoculated with CWD and
169 Tg650 (human PrP) mice inoculated with cattle BSE did not develop high rates of
170 clinical disease or significant PrP^{TSE} in brain, but a large proportion of inoculated
171 mice had PrP^{TSE} detectable in spleen. 60 mice inoculated at Roslin with the atypical
172 TSE agents (either showing clinical signs or a selection of the oldest mice, ranging
173 from 321dpi to 730dpi), were analysed for the presence of peripheral agent replication
174 using the IDEXX HerdChek Bovine Spongiform Encephalopathy (BSE) Antigen Test
175 Kit, which is an antigen capture enzyme immunoassay (EIA) used to detect
176 aggregated PrP in post-mortem tissues. Spleens derived from human PrP Tg mice
177 challenged with BASE, BSE-H, CWD and atypical scrapie were homogenised in
178 sterile saline in a Rybolyser (Hybaid, Middlesex, UK) to achieve a 30% homogenate
179 and processed in the IDEXX HerdChek assay. All assay readouts were negative for
180 the presence of disease related PrP. Hence there was no evidence of increased cross-
181 species transmission in lymphoid tissues of gene-targeted human Tg mice inoculated
182 with these atypical TSE agents.

183
184 Interestingly several human PrP Tg mice were scored as showing positive clinical
185 signs of disease despite the lack of disease associated pathology, most notably in
186 those mice inoculated with atypical scrapie (Table 2). Indeed, out of a total of 662
187 mice inoculated with six atypical scrapie field isolates, 25 had clinical signs of TSE
188 (10 x HuMM, 9 x HuMV, 4 x HuVV, 1 x Bov6, 1 x 129/Ola). If the data were simply
189 due to scoring errors we would expect similar numbers of cases in all groups.
190 However, on the assumption that mice responded and were scored independently of
191 one another (i.e., all mice had an equal chance of being scored as showing clinical
192 signs) the distribution of clinical cases between the 30 groups of atypical scrapie
193 inoculated Tg mice is statistically significant at $p \leq 0.003$. The relevance of this
194 observation is unclear. It is possible that the clinical signs observed in these mice are
195 due to non-TSE intercurrent illnesses encountered because of the extended nature of
196 these transmission experiments. However scoring protocols are robust and do not
197 usually yield high numbers of false negative results when compared with disease
198 pathology post mortem. It is possible that these clinical signs indicate a different TSE
199 disease phenotype whereby the pathological signs associated with disease cannot be
200 detected using our conventional methods of tissue analysis. This hypothesis is being
201 further investigated by subpassage from selected cases to identify any evidence of

202 subclinical disease or low level agent replication. While control ovine Tg mice were
203 not available to include in the original transmission panel at The Roslin Institute, 5/6
204 of the atypical scrapie field isolates were inoculated into Tg338 ovine transgenic mice
205 at AHVLA (Griffiths *et al.*, 2010) (sample numbers 2 and 5 in Griffiths *et al.*, and
206 Spiropoulos-personal communication). All five isolates transmitted efficiently to
207 Tg338 transgenic mice (incubation times ~200 days post inoculation), proving the
208 infectivity of the source material.

209
210 Our results indicate that BASE, H-type BSE, CWD and atypical scrapie do not
211 transmit to gene-targeted Tg mice expressing wild type levels of human PrP, however
212 subpassage experiments are currently in progress to assay for any possible subclinical
213 infection in mice that received these agents. The lack of BASE transmission to
214 HuMM Tg mice has been confirmed following independent transmissions to mice in
215 three different laboratories (Roslin Institute, “Carlo Besta” Neurological Institute,
216 Istituto Superiore di Sanita). Surprisingly, other studies have shown the transmission
217 of BASE into microinjection-derived human PrP Tg mice (Tg40) (Kong *et al.*, 2008),
218 which were reported to also express human PrP-129M at wildtype levels. Despite the
219 apparent similarities in expression levels between these lines, previous studies have
220 produced other conflicting results between the Tg40 line and our targeted HuMM Tg
221 line. While Tg40 mice were reported to be highly susceptible to sCJD(MM2) (Kong
222 *et al.*, 2008), HuMM mice inoculated with sCJD(MM2) showed no clinical signs of
223 disease (Bishop *et al.*, 2010). The reasons for this discrepancy are not clear, but may
224 be due to different mouse genetic background, or a more subtle difference in PrP
225 expression levels in each Tg line. Other studies have shown the transmission of BASE
226 into overexpressing human PrP Tg mice (Tg 650; ~6 fold overexpression), with
227 prolonged incubation times of 600-700 days. However similarly to our findings they
228 did not achieve transmission of H-type BSE into Tg650 mice (Beringue *et al.*, 2008).
229 Previous studies have shown CWD TSEs do not transmit to mice overexpressing
230 human PrP (Sandberg *et al.*, 2010; Tamguney *et al.*, 2006). Furthermore, other
231 studies investigating transmissibility of elk CWD TSEs, did not observe transmission
232 into Tg40 mice (human PrP Tg) (Kong *et al.*, 2005). Studies have shown levels of
233 PrP^{TSE} in lymphoid tissues are much higher in CWD-infected deer compared to elk
234 (Race *et al.*, 2007), suggesting deer may be more likely to transmit disease to other
235 cervids and noncervids. In the present study we challenged our human PrP Tg mice
236 with CWD-infected white-tailed deer, but did not observe any signs of disease.
237 However it may be possible that CWD can be caused by multiple strains (Angers *et*
238 *al.*, 2010) and as distinct cervid TSE strains become recognised and characterised,
239 further studies will be required to assess human risk.

240
241 In this study, we examined, for the first time, the transmissibility of BASE, BSE-H,
242 CWD and atypical scrapie into gene-targeted Tg mice expressing human PrP and
243 show that these mice are highly resistant to infection with these animal TSEs. In
244 contrast to recently published research (Béringue *et al.*, 2012), we did not find any
245 evidence of disease within lymphoid tissue of gene-targeted HuTg mice inoculated
246 with these atypical TSE agents. While other studies have conducted similar
247 experiments using overexpressing human PrP Tg mouse lines, the Tg mice used in
248 this study are produced by gene replacement and do not suffer from any adverse
249 phenotypes which can be associated with overexpression or ectopic expression of the
250 transgene in standard Tg lines. While overexpression may increase sensitivity of these
251 models by reducing incubation times, these levels of expression do not occur in host

252 species. Gene-targeted models may therefore more closely represent infection and
253 disease progression in nature. Indeed, previous studies have shown transmission of
254 sporadic CJD, vCJD and sheep BSE into gene-targeted human PrP Tg mice,
255 demonstrating that these mice do live long enough to show signs of infection,
256 supporting the use of targeted mouse models to analyse TSE disease transmission
257 (Bishop *et al.*, 2010; Bishop *et al.*, 2006; Plinston *et al.*, 2011). In conclusion, the
258 results presented here strongly suggest the presence of a significant transmission
259 barrier between these ruminant TSEs and humans. However, while TSEs are still
260 present in the environment, the potential for cross-species transmission and
261 emergence of new TSE isolates remains, thus supporting the need for continued
262 surveillance of these agents.

263

264 **Acknowledgements**

265

266 The authors would like to acknowledge I. McConnell, V. Thomson, S. Cumming, S.
267 Carpenter, R. Greenan, K. Hogan, I. Itró, E. Laconi, M. Venditti, A. Valanzano, M.
268 Bonanno, and N. Bellizzi for experimental setup, care and scoring of the animals; A.
269 Coghill, A. Boyle, S. Mack and G. McGregor for histology processing and scoring; I.
270 Martino, D. Biondo, and A. De Pascalis for western blotting. We thank the Wisconsin
271 Department of Natural Resources for the CWD brain sample. All mouse experiments
272 were reviewed and approved by the Local Ethical Review Committee and performed
273 under licence from the United Kingdom Home Office in accordance with the United
274 Kingdom Animals (Scientific Procedures) Act 1986 and by the Service for
275 Biotechnology and Animal Welfare of the Istituto Superiore di Sanità, authorized by
276 the Italian Ministry of Health according to Legislative Decree 116/12 which has
277 implemented in Italy the European Directive 86/609/EEC on laboratory animals
278 protection. This work was funded by contract M03054 from the Food Standards
279 Agency (FSA), UK; contract SE1441 from the Department for Environment, Food
280 and Rural Affairs (Defra); contract 2004–506579 “NeuroPrion” from the European
281 Union, and from the Italian Ministry of Health; and contract NIAID PO1 AI077774-01
282 “Pathogenesis, Transmission and Detection of Zoonotic Prion Diseases”. The authors
283 declare that this study was carried out under the following Research Project funded by
284 the Italian Ministry of Health: Ricerca Finalizzata 2009 - 09F01 “The novel
285 emergence of atypical animal and human TSEs. A clinical, pathological, molecular,
286 and experimental approach to define interspecies similarities and strain connections”

287

288

289 **References**

290

- 291 **Angers, R. C., Browning, S. R., Seward, T. S., Sigurdson, C. J., Miller, M. W.,**
292 **Hoover, E. A. & Telling, G. C. (2006).** Prions in skeletal muscles of deer with
293 chronic wasting disease. *Science* **311**, 1117.
294 **Angers, R. C., Seward, T. S., Napier, D., Green, M., Hoover, E., Spraker, T.,**
295 **O'Rourke, K., Balachandran, A. & Telling, G. C. (2009).** Chronic wasting disease
296 prions in elk antler velvet. *Emerg Infect Dis* **15**, 696-703.
297 **Angers, R. C., Kang, H. E., Napier, D., Browning, S., Seward, T., Mathiason, C.,**
298 **Balachandran, A., McKenzie, D., Castilla, J. & other authors (2010).** Prion strain
299 mutation determined by prion protein conformational compatibility and primary
300 structure. *Science* **328**, 1154-1158.

301 **Benestad, S., Sarradin, P., Thu, B., Schonheit, J., Tranulis, M. & Bratberg, B.**
302 **(2003).** Cases of scrapie with unusual features in Norway and designation of a new
303 type, Nor98. *Vet Rec* **153**, 202 - 208.

304 **Benestad, S. L., Arsaç, J. N., Goldmann, W. & Noremark, M. (2008).**
305 Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. *Vet Res*
306 **39**, 19.

307 **Beringue, V., Herzog, L., Reine, F., Le-Dur, A., Casalone, C., Vilotte, J. L. &**
308 **Laude, H. (2008).** Transmission of atypical bovine prions to mice transgenic for
309 human prion protein. *Emerg Infect Dis* **14**, 1898-1901.

310 **Béringue, V., Herzog, L., Jaumain, E., Reine, F., Sibille, P., Le Dur, A., Vilotte,**
311 **J.-L. & Laude, H. (2012).** Facilitated Cross-Species Transmission of Prions in
312 Extraneural Tissue. *Science* **335**, 472-475.

313 **Biacabe, A. G., Laplanche, J. L., Ryder, S. & Baron, T. (2004).** Distinct molecular
314 phenotypes in bovine prion diseases. *EMBO Rep* **5**, 110-115.

315 **Bishop, M. T., Will, R. G. & Manson, J. C. (2010).** Defining sporadic Creutzfeldt-
316 Jakob disease strains and their transmission properties. *Proc Natl Acad Sci U S A* **107**,
317 12005-12010.

318 **Bishop, M. T., Hart, P., Aitchison, L., Baybutt, H., Plinston, C., Thomson, V.,**
319 **Tuzi, N., Head, M., Ironside, J. & other authors (2006).** Predicting susceptibility
320 and incubation time of human-to-human transmission of vCJD. *Lancet Neurology* **5**,
321 393-398.

322 **Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie,**
323 **A., McCardle, L., Chree, A., Hope, J. & other authors (1997).** Transmissions to
324 mice indicate that 'new variant' CJD is caused by the BSE agent. *Nature* **389**, 498-
325 501.

326 **Casalone, C., Zanusso, G., Acutis, P., Ferrari, S., Capucci, L., Tagliavini, F.,**
327 **Monaco, S. & Caramelli, M. (2004).** Identification of a second bovine amyloidotic
328 spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob
329 disease. *Proc Natl Acad Sci U S A* **101**, 3065-3070.

330 **Denkers, N. D., Seelig, D. M., Telling, G. C. & Hoover, E. A. (2010).** Aerosol and
331 nasal transmission of chronic wasting disease in cervidized mice. *J Gen Virol* **91**,
332 1651-1658.

333 **Dickinson, A. G., Meikle, V. M. & Fraser, H. (1968).** Identification of a gene which
334 controls the incubation period of some strains of scrapie agent in mice. *J Comp Pathol*
335 **78**, 293-299.

336 **Fraser, H. & Dickinson, A. G. (1967).** Distribution of experimentally induced
337 scrapie lesions in the brain. *Nature* **216**, 1310-1311.

338 **Griffiths, P. C., Spiropoulos, J., Lockey, R., Tout, A. C., Jayasena, D., Plater, J.**
339 **M., Chave, A., Green, R. B., Simonini, S. & other authors (2010).** Characterization
340 of atypical scrapie cases from Great Britain in transgenic ovine PrP mice. *J Gen Virol*
341 **91**, 2132-2138.

342 **Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C. & Hoover, E. A. (2009).**
343 Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay.
344 *PLoS ONE* **4**, e4848.

345 **Haley, N. J., Mathiason, C. K., Carver, S., Zabel, M., Telling, G. C. & Hoover, E.**
346 **A. (2011).** Detection of Chronic Wasting Disease Prions in Salivary, Urinary, and
347 Intestinal Tissues of Deer: Potential Mechanisms of Prion Shedding and
348 Transmission. *J Virol* **85**, 6309-6318.

349 **Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C. L., Gowland, I., Collinge, J.,**
350 **Doey, L. J. & Lantos, P. (1997).** The same prion strain causes vCJD and BSE.
351 *Nature* **389**, 448-450.

352 **Jacobs, J. G., Langeveld, J. P., Biacabe, A. G., Acutis, P. L., Polak, M. P.,**
353 **Gavier-Widen, D., Buschmann, A., Caramelli, M., Casalone, C. & other authors**
354 **(2007).** Molecular discrimination of atypical bovine spongiform encephalopathy
355 strains from a geographical region spanning a wide area in Europe. *J Clin Microbiol*
356 **45**, 1821-1829.

357 **Kong, Q., Huang, S., Zou, W., Vanegas, D., Wang, M., Wu, D., Yuan, J., Zheng,**
358 **M., Bai, H. & other authors (2005).** Chronic wasting disease of elk: transmissibility
359 to humans examined by transgenic mouse models. *J Neurosci* **25**, 7944-7949.

360 **Kong, Q., Zheng, M., Casalone, C., Qing, L., Huang, S., Chakraborty, B., Wang,**
361 **P., Chen, F., Cali, I. & other authors (2008).** Evaluation of the human transmission
362 risk of an atypical bovine spongiform encephalopathy prion strain. *J Virol* **82**, 3697-
363 3701.

364 **Mathiason, C. K., Hays, S. A., Powers, J., Hayes-Klug, J., Langenberg, J.,**
365 **Dahmes, S. J., Osborn, D. A., Miller, K. V., Warren, R. J. & other authors**
366 **(2009).** Infectious prions in pre-clinical deer and transmission of chronic wasting
367 disease solely by environmental exposure. *PLoS One* **4**, e5916.

368 **Mathiason, C. K., Powers, J. G., Dahmes, S. J., Osborn, D. A., Miller, K. V.,**
369 **Warren, R. J., Mason, G. L., Hays, S. A., Hayes-Klug, J. & other authors (2006).**
370 Infectious Prions in the Saliva and Blood of Deer with Chronic Wasting Disease.
371 *Science* **314**, 133-136.

372 **Miller, M. W. & Williams, E. S. (2003).** Prion disease: horizontal prion transmission
373 in mule deer. *Nature* **425**, 35-36.

374 **Miller, M. W., Wild, M. A. & Williams, E. S. (1998).** Epidemiology of chronic
375 wasting disease in captive Rocky Mountain elk. *J Wildl Dis* **34**, 532-538.

376 **Plinston, C., Hart, P., Chong, A., Hunter, N., Foster, J., Piccardo, P., Manson, J.**
377 **C. & Barron, R. M. (2011).** Increased Susceptibility of Human-PrP Transgenic Mice
378 to Bovine Spongiform Encephalopathy Infection following Passage in Sheep. *J Virol*
379 **85**, 1174-1181.

380 **Race, B., Meade-White, K., Race, R. & Chesebro, B. (2009a).** Prion infectivity in
381 fat of deer with Chronic Wasting Disease. *J Virol* **1**, 1.

382 **Race, B., Meade-White, K. D., Miller, M. W., Barbian, K. D., Rubenstein, R.,**
383 **LaFauci, G., Cervenakova, L., Favara, C., Gardner, D. & other authors (2009b).**
384 Susceptibilities of nonhuman primates to chronic wasting disease. *Emerg Infect Dis*
385 **15**, 1366-1376.

386 **Race, B. L., Meade-White, K. D., Ward, A., Jewell, J., Miller, M. W., Williams,**
387 **E. S., Chesebro, B. & Race, R. E. (2007).** Levels of abnormal prion protein in deer
388 and elk with chronic wasting disease. *Emerg Infect Dis* **13**, 824-830.

389 **Sandberg, M. K., Al-Doujaily, H., Sigurdson, C. J., Glatzel, M., O'Malley, C.,**
390 **Powell, C., Asante, E. A., Linehan, J. M., Brandner, S. & other authors (2010).**
391 Chronic wasting disease prions are not transmissible to transgenic mice
392 overexpressing human prion protein. *J Gen Virol* **91**, 2651-2657.

393 **Sigurdson, C. J., Williams, E. S., Miller, M. W., Spraker, T. R., O'Rourke, K. I.**
394 **& Hoover, E. A. (1999).** Oral transmission and early lymphoid tropism of chronic
395 wasting disease PrPres in mule deer fawns (*Odocoileus hemionus*). *J Gen Virol* **80** (
396 Pt 10), 2757-2764.

397 **Spraker, T. R., Zink, R. R., Cummings, B. A., Wild, M. A., Miller, M. W. &**
398 **O'Rourke, K. I. (2002).** Comparison of histological lesions and

399 immunohistochemical staining of proteinase-resistant prion protein in a naturally
 400 occurring spongiform encephalopathy of free-ranging mule deer (*Odocoileus*
 401 *hemionus*) with those of chronic wasting disease of captive mule deer. *Vet Pathol* **39**,
 402 110-119.

403 **Stack, M. J., Focosi-Snyman, R., Cawthraw, S., Davis, L., Chaplin, M. J. &**
 404 **Burke, P. J. (2009).** Third atypical BSE case in Great Britain with an H-type
 405 molecular profile. *Vet Rec* **165**, 605-606.

406 **Tamguney, G., Giles, K., Bouzamondo-Bernstein, E., Bosque, P. J., Miller, M.**
 407 **W., Safar, J., DeArmond, S. J. & Prusiner, S. B. (2006).** Transmission of elk and
 408 deer prions to transgenic mice. *J Virol* **80**, 9104-9114.

409 **Trifilo, M. J., Ying, G., Teng, C. & Oldstone, M. B. (2007).** Chronic wasting
 410 disease of deer and elk in transgenic mice: oral transmission and pathobiology.
 411 *Virology* **365**, 136-143.

412 **Wilson, R., Hart, P., Piccardo, P., Hunter, N., Casalone, C., Baron, T. & Barron,**
 413 **R. (2012).** Bovine PrP expression levels in Transgenic mice Influence Transmission
 414 Characteristics of Atypical BSE. *Journal of General Virology*.

415

416

417 **Table 1.** Transmission of BASE, BSE-H, CWD and atypical scrapie to human and
 418 bovine PrP Tg mice.

419

TSE Isolate	Mouse Line									
	HuMM		HuMV		HuVV		Bov6‡		129/Ola‡	
	Survival Time	No. affected								
BASE (Roslin)	>687	0/24	>672	0/24	>763	0/24	547±18*	24/24†	>687	1/24†
BASE (Milan)	>753	0/23	>700	0/23	>726	0/19	na	na	na	na
BASE# 1 (Rome)	>633	0/19	>680	0/14	>707	0/17	na	na	na	na
BASE#2 (Rome)	>604	0/16	>854	0/29	>740	0/20	na	na	na	na
BSE-C (Rome)	>592	0/14	>856	0/15	>509	0/13	na	na	na	na
BSE-H	>722	0/24	>708	0/24	>708	0/24	561±15*	17/23†	675±19*	5/23†
CWD	>680	0/24	>730	0/24	>722	0/24	>716	0/23	457,707	2/24†
Sheep passaged atypical scrapie	>693	0/24	>693	0/24	>693	0/24	>693	0/24	>693	0/24
Atypical scrapie ARR/ARR1	>651	0/23	>724	0/21	>829	0/24	>781	0/24	>753	0/24
Atypical scrapie AHQ/AHQ1	>822	0/24	>718	0/24	>682	0/22	>757	0/23	>710	0/11
Atypical scrapie ARR/ARR2	>722	0/24	>744	0/24	>841	0/23	>756	0/22	>673	0/12
Atypical scrapie AHQ/AHQ2	>786	0/22	>768	0/23	>700	0/24	>805	0/24	>779	0/21
Atypical scrapie AFRQ/AFRQ1	>815	0/24	>717	0/23	>759	0/23	>757	0/23	>772	0/24

Atypical scrapie AFRQ/AFRQ2	>750	0/23	>722	0/23	>756	0/24	>726	0/24	>756	0/12
--------------------------------	------	------	------	------	------	------	------	------	------	------

420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437

>n Represents the survival in days of the oldest mouse in groups where pathological signs of disease were not observed in any animals.
* Measured as days ± standard errors of the means and calculated from mice showing pathological signs of disease (vacuolation and/or PrP deposition)
† Number of mice showing pathological signs of disease (vacuolation and/or PrP deposition)/number of mice inoculated.
‡ Results for BASE and H-type BSE inoculations into Bov6 mice and 129/Ola mice have previously been published (Wilson *et al.*, 2012).

Table 2. Cases of clinically positive signs of disease in human and bovine PrP Tg mice inoculated with atypical scrapie

	HuMM		HuMV		HuVV		Bov6		129/Ola	
	Clin +ve	n	Clin +ve	n	Clin +ve	n	Clin +ve	n	Clin +ve	n
Atypical scrapie ARR/ARR-1	0	23	1	21	0	24	0	24	0	24
Atypical scrapie AHQ/AHQ-1	1	24	3	24	3	22	0	23	0	11
Atypical scrapie ARR/ARR-2	2	24	2	24	0	23	0	22	0	12
Atypical scrapie AHQ/AHQ-2	1	22	2	23	1	24	0	24	1	21
Atypical scrapie AFRQ/AFRQ-1	6	24	1	23	0	23	1	23	0	24
Atypical scrapie AFRQ/AFRQ-2	0	23	0	23	0	24	0	24	0	12
Total Clin+ve atypical scrapie cases	10	140	9	138	4	140	1	140	1	104

438
439
440
441
442
443
444
445